Physician profile
Ethan Webb
NPI 1902855596
$2,014.42
in general payments reported to CMS, 2019-2025
31 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $161 · 2022: $113 · 2023: $243 · 2024: $600 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $228.98 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $197.07 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $158.89 | 2019-2020 | |
| Amgen INC. | $158.24 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $122.91 | 2019-2025 | |
| Janssen Biotech, INC. | $104.69 | 2023-2025 | Stelara, Simponi Aria, Simponi |
| Abbott Laboratories | $95.35 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $95.05 | 2019-2025 | |
| Lilly USA, LLC | $83.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Biosense Webster, INC. | $80.39 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.81 | 2024-2025 | Entyvio, Eohilia |
| Glaxosmithkline, LLC. | $71.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.64 | 2019-2024 | Xarelto |
| Idorsia Pharmaceuticals US INC | $58.52 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $58.19 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $40.22 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $34.40 | 2020-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.95 | 2023-2024 | Synjardy, Jardiance |
| Amarin Pharma, INC. | $30.70 | 2019 | |
| Merck Sharp & Dohme LLC | $24.36 | 2019 | |
| Lucid Diagnostics INC. | $22.21 | 2024 | |
| Therapeuticsmd, INC. | $21.86 | 2019 | |
| Jazz Pharmaceuticals INC. | $20.74 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $20.50 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.45 | 2025 | Caplyta |
| Agios Pharmaceuticals, INC. | $17.14 | 2024 | |
| Ferring Pharmaceuticals INC. | $17.10 | 2024 | Rebyota |
| Almatica Pharma LLC | $17.09 | 2024 | Loreev Xr |
| Sanofi-Aventis U.S. LLC | $15.56 | 2019 | |
| Nevro Corp. | $12.84 | 2019 | |
| Daiichi Sankyo INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.